ProPhase Labs, Inc. (PRPH) Fair Value 2026

PRPH · Diagnostics & Research ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.8 /10

32 fundamental signals · 1 models active

Value Trap Risk

WARN (41/100)

Quick Summary — As of 2026-08-27, ProPhase Labs, Inc. (PRPH) trades at $0.02. QOC: 4.8/10. Value Trap Risk: 41/100 (WARN). 1/13 models active.

Key Facts

Ticker
PRPH
Price
$0.02
Quality Score
4.8/10
Value Trap Risk
41/100
Models Active
1/13
Last Updated
Strength: 1 independent models provide multi-angle coverage
Risk: Value Trap score of 41 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give PRPH?

1 Intrinsic Value Models vs. Current Price ($0.02)

Core Models (Unlocked)
Model Fair Value Upside
Relative · Low Conviction
 $0.01 -52.6%

All Models Active

All 1 models are displayed above.

What Is ProPhase Labs, Inc. (PRPH) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, ProPhase Labs, Inc.'s intrinsic value is estimated at $0.01. Trading at its current price of $0.02, the valuation engine raises significant caution: 1 of 1 models flag downside risk, projecting a median implied return of -52.6%.

What Do the Models Say About PRPH?

1 of 13 models are currently active for PRPH. All 1 active models suggest the stock trades above fair value. See which stocks rank higher →

How Does PRPH Rank in Diagnostics & Research?

Among 52 Diagnostics & Research stocks, PRPH ranks #45 by Quality of Company score. CirclFi's QOC score of 4.8/10 evaluates 32 fundamental signals. A score of 4.8 reflects mixed fundamentals.

The Diagnostics & Research sector introduces analytical considerations specific to biopharma enterprise businesses. For ProPhase Labs, Inc., metrics like patent cliff exposure provide important context that general-purpose valuation models may underweight.

Is PRPH a Value Trap?

CirclFi's Value Trap algorithm assigns PRPH a score of 41/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for ProPhase Labs, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, ProPhase Labs, Inc. scores 4.8 out of 10 on our 32-signal quality assessment, a moderate rating that shows mixed signals across our quality framework with notable weaknesses. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every PRPH valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across PRPH's 1 active models, average confidence is 18%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy ProPhase Labs, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Diagnostics & Research Stocks Should You Also Analyze?

11 related Diagnostics & Research stocks with 13-model coverage

FRNMFreenome, Inc.QOC 4.8NSTMNovelStem International Corp.QOC 4.2ISPCiSpecimen Inc.QOC 4.8NDRAENDRA Life Sciences Inc.QOC 4.0BIAFbioAffinity Technologies, Inc.QOC 5.0FUNIHypha Labs, Inc.QOC 3.9MTDMettler-Toledo International Inc.QOC 8.7CSTLCastle Biosciences, Inc.QOC 7.4WGSGeneDx Holdings Corp.QOC 6.4IDXXIDEXX Laboratories, Inc.QOC 9.5MEDPMedpace Holdings, Inc.QOC 9.3

Read investment analysis: FRNM · NSTM · ISPC · NDRA · BIAF · FUNI · MTD · CSTL · WGS · IDXX · MEDP

Which Other Stocks Have a Similar Quality Score to PRPH?

7 companies across all industries closest to PRPH’s Quality of Company score of 4.8/10.

TELOTelomir Pharmaceuticals, Inc.QOC 4.8ZSTKZeroStack Corp.QOC 4.8EWSBEWSB Bancorp, Inc.QOC 4.8ATVKGlobalTek Ventures, Inc.QOC 4.7AASPAgassi Sports Entertainment Corp.QOC 4.8PGOLPatriot Gold Corp.QOC 4.7NVDANVIDIA CorporationQOC 10.0

Read investment analysis: TELO · ZSTK · EWSB · ATVK · AASP · PGOL · NVDA

What Else Do Investors Ask About ProPhase Labs, Inc.’s Valuation?

What is ProPhase Labs, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for ProPhase Labs, Inc. (PRPH). The Quality of Company score is 4.8/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is PRPH overvalued or undervalued right now?

At $0.02, 0 of 1 active models suggest PRPH may be undervalued, while 1 indicate potential overvaluation. The assessment depends on which methodology best fits ProPhase Labs, Inc.'s business model in Diagnostics & Research.

What does a Quality of Company score of 4.8 mean for PRPH?

ProPhase Labs, Inc.'s QOC of 4.8/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on PRPH?

CirclFi analyzes PRPH with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is PRPH a value trap in 2026?

ProPhase Labs, Inc.'s Value Trap score is 41/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns ProPhase Labs, Inc. (PRPH) a Quality of Company score of 4.8/10 across 32 fundamental signals as of 2026-08-27.” Source: circlfi.com/stock/PRPH/ · Methodology
Primary sources for this PRPH valuation
  • Financial statements: ProPhase Labs, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0000868278) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for PRPH as of ; valuations recomputed .